For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$41.65
Thesis
Viking Therapeutics is developing VK2735, a dual GLP-1/GIP receptor agonist, in both injectable and oral formulations. As a pure-play, its outlook is tied to the clinical progression of this metabolic candidate.
Catalysts
- VK2735 injectable clinical trial readouts
- VK2735 oral formulation data
- Advancement into later-stage development
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.